8-K: Phathom Pharmaceuticals Reports Strong Q2 2024 Results Driven by VOQUEZNA Launch

Phathom Pharmaceuticals saw a significant increase in revenue and prescriptions for VOQUEZNA in the second quarter of 2024, driven by expanded FDA approvals and commercial coverage.

Summary

• Phathom Pharmaceuticals reported a net revenue of $7.3 million for the second quarter of 2024, a substantial increase from $1.9 million in the first quarter of 2024.
• The company saw a 184% increase in total prescriptions written for VOQUEZNA products since the last quarterly report, reaching over 122,000.
• Filled prescriptions for VOQUEZNA products increased by over 240% since the last quarterly report, with over 60,000 prescriptions filled to date.
• The prescriber base for VOQUEZNA has grown by over 115% since the last quarterly report, with more than 8,200 cumulative prescribers.
• Commercial coverage for VOQUEZNA now includes over 116 million U.S. lives, representing an estimated 77% of total U.S. commercial lives.
• The FDA approved VOQUEZNA 10mg tablets for the treatment of heartburn associated with Non-Erosive GERD in adults.
• Phathom plans to initiate a Phase 3 study for As Needed dosing of VOQUEZNA for active heartburn episodes and a Phase 2 study for Eosinophilic Esophagitis (EoE) by the end of the year.
• Research and development expenses decreased to $7.4 million in Q2 2024 from $12.8 million in Q2 2023.
• Selling, general, and administrative expenses increased to $75.9 million in Q2 2024 from $18.9 million in Q2 2023 due to commercial launch activities.
• The net loss for the second quarter of 2024 was $91.4 million, compared to $41.0 million for the same period in 2023.
• The company's cash and cash equivalents were $276.2 million as of June 30, 2024, with up to an additional $125 million available under a term loan.
• Phathom believes it has sufficient capital to fund operations through the end of 2026.

Sentiment

Score: 7

Explanation: The document shows strong positive momentum in product adoption and market access, but the high net loss and significant increase in operating expenses temper the overall sentiment. The company is making good progress but needs to manage costs and continue to drive revenue growth.

Positives

• The company experienced significant revenue growth, with a greater than 280% increase in net revenue from Q1 to Q2 2024.
• There was a substantial increase in prescriptions written and filled for VOQUEZNA products, indicating strong market demand.
• The FDA approval of VOQUEZNA for Non-Erosive GERD expands the potential market significantly.
• The company has secured broad commercial coverage for VOQUEZNA, ensuring access for a large portion of the U.S. population.
• Phathom has a strong cash position and believes it has sufficient capital to fund operations through the end of 2026.
• The company is planning to initiate new clinical trials to further expand the use of VOQUEZNA.

Negatives

• The company reported a net loss of $91.4 million for the second quarter of 2024, which is significantly higher than the $41.0 million loss in the same period of 2023.
• Selling, general, and administrative expenses increased substantially due to the commercial launch of VOQUEZNA.
• The company's cash and cash equivalents decreased from $381.4 million at the end of 2023 to $276.2 million as of June 30, 2024.

Risks

• The company's ability to successfully commercialize VOQUEZNA depends on factors such as coverage and reimbursement levels and market acceptance.
• Phathom may use its capital resources sooner than expected, potentially requiring them to reduce expenses or raise additional capital.
• There are inherent risks in the clinical development of vonoprazan, including unexpected adverse side effects or inadequate efficacy.
• The company is dependent on third parties for product manufacturing, research, and testing.
• Regulatory developments in the U.S. and foreign countries could impact the company's operations.
• The company's estimates regarding patient population and commercial coverage could prove to be inaccurate.

Future Outlook

Phathom plans to initiate a Phase 3 study for As Needed dosing of VOQUEZNA for active heartburn episodes and a Phase 2 study for Eosinophilic Esophagitis (EoE) by the end of the year. The company believes it has sufficient capital to fund operations through the end of 2026.

Management Comments

• Terrie Curran, President and CEO of Phathom, stated that the company's progress highlights the strong and growing demand for VOQUEZNA.
• Management is excited by the growth across all key metrics and the positive feedback from those who have experienced the benefits of VOQUEZNA.
• Management believes they are in a strong position to expand their patient base and ensure broad access to their first-in-class therapy.

Industry Context

The approval and launch of VOQUEZNA represent a significant development in the treatment of gastrointestinal diseases, particularly GERD, which affects a large patient population. The company is positioning VOQUEZNA as a first-in-class therapy and a major innovation in GERD treatment, potentially disrupting the market dominated by older treatments like PPIs.

Comparison to Industry Standards

• Phathom's VOQUEZNA is a potassium-competitive acid blocker (PCAB), a newer class of drugs compared to traditional proton pump inhibitors (PPIs) which have been the standard of care for GERD for over 30 years.
• The rapid uptake of VOQUEZNA prescriptions, with over 122,000 written to date, suggests a strong market interest in this new treatment option, potentially exceeding the initial launch trajectories of some comparable pharmaceutical products.
• The expansion of commercial coverage to 77% of U.S. commercial lives is a significant achievement, placing Phathom in a competitive position against established players in the GI market.
• While the company's revenue is growing rapidly, the high SG&A expenses reflect the significant investment required for a successful commercial launch, which is typical for pharmaceutical companies in the early stages of product commercialization.
• The planned Phase 3 study for As Needed dosing of VOQUEZNA is a unique approach that could differentiate it from existing treatments, as PPIs are not approved for this type of dosing.

Stakeholder Impact

• Shareholders may be encouraged by the strong revenue growth and market adoption of VOQUEZNA, but concerned about the increasing net loss.
• Employees may be positively impacted by the company's growth and expansion.
• Customers (patients) will benefit from the availability of a new treatment option for GERD.
• Suppliers may see increased demand for their products and services.
• Creditors may be reassured by the company's cash position and revenue growth.

Next Steps

• Phathom plans to initiate a Phase 3 study for As Needed dosing of VOQUEZNA for active heartburn episodes later this year.
• The company plans to initiate a Phase 2 study to investigate VOQUEZNA as a potential treatment for Eosinophilic Esophagitis (EoE) by the end of the year.
• Phathom will continue to focus on expanding commercial coverage and increasing market penetration for VOQUEZNA.

Key Dates

Keywords

VOQUEZNA, vonoprazan, GERD, Non-Erosive GERD, Erosive GERD, H. pylori, FDA approval, commercial launch, prescription, pharmaceuticals, gastrointestinal, biopharmaceutical